About Us

RemAb Therapeutics is a European, multi-asset, preclinical-stage biopharmaceutical company. 

 

Our aim is to become leaders in the sector providing sanitary solutions by eliminating specific antibodies. We expect to achieve this goal by introducing multiple products that are pioneers in the sector and reaching their commercialization worldwide.

 

Solving health problems

is our Mission

RemAb Therapeutics is committed to providing a novel treatment to combat a global threat.

Our most advanced candidate, RA-01, could become the first preventive solution for infections associated with Gram-negative bacteria in the ICU. We have obtained data both in vitro and in vivo that prove the efficacy of our first candidate.

RemAb Therapeutics is developing, with the same technology, three more programs that point to other clinical needs not covered. These programs will be included in the portfolio soon.

 

We truly believe that our strategy will have a great impact on the patient's health and commercial applications to treat different pathologies mediated by antibodies.

 

 

 

Meet our Team

Dr. Rafael Mañez
President and CMO

  • Read more

    Ph.D. in Medicine (University Autonomous of Barcelona).

    1990-1994: Assistant Professor of Surgery in the Thomas Starzl Transplantation Institute of the University of Pittsburgh, USA.

    1996-2003 Director of Transplantation, in La Coruña University Hospital, Spain.

    2003-act. Director of Critical Care Medicine at Bellvitge University Hospital, Spain.

    Expert in transplantation and xenotransplantation systems, and in the role of antibodies in the rejection of allografts and xenografts, and in the development of infections.

    Dr. Mañez holds 2 patents and is the author of 135 PubMed referenced articles and has 19 additional publications as Collaborator.

Pablo Madrazo
CEO

  • Read more

    Graduate in Business Administration (University of Barcelona) with a double degree in international finance by Hoge school van Utrecht.

    Started his career in financial positions and Consulting in PwC. He has spent 13 years in Asia and he contributed in the opening and development of the activities in China for Werfen Group, as Financial Director and COO.

    He is founder of Eurohealthcare that provides tailor made services in the life science field, with comprehensive transaction advice and funding. He counts with strong network of industry contacts in Europe and Asia (from companies to investment banks)

    He is advisor in several early stage healthcare projects and already marketed medical devices, and diagnostics companies as well an algorithms company for cancer diagnosis

Dr. Daniel Bello
CSO

  • Read more

    PhD in Molecular and Cellular Biology (Miguel Hernandez University, Spain).

    His expertise is mainly linked to the protein biotechnology, microbiology, and immunology fields. He is an expert on the role of natural anti-glycan antibodies in the progression of infectious diseases and xenotransplantation.

    He has been awarded different grants from the European Molecular Biology Organization, EMBO (2008); the International Union of Biochemistry and Molecular Biology, IUBMB (2006) and The Swiss Government Excellence Scholarships (2006).

    He carries out consultant activities to local biotech companies. Dr. Bello holds 2 patents and is the author of several peer-reviewed scientific publications.

Sara Olivera-Ardid
Technician

  • Read more

    MSc in Advanced Microbiology: Sanitary Speciality (University of Barcelona)

    Previously, she has been working as a Laboratory technician in Envigo CRS and IDIBELL.

    She is an expert on antibody quantification and purification, handling and conservation of biological samples, development of bactericidal assays, evaluation of the binding of antibodies by flow cytometry and biomass quantification.

 

Strategic Consultants

 

Xavier Luria
Regulatory

  • Read more

    Bachelor of Medicine (Autonomous University of Barcelona).

    Dr. Luria was Head of Safety and Efficacy of Drugs at the European Medicines Agency (EMA) during 2005-2012.

    He is a recognized expert in regulatory systems and risk-benefit assessment (modeling, development and methodologies) and has been a professor at the University of California, San Francisco. In addition, he advises governments in Europe and Latin America and is a professor of regulation of the life sciences industry at IE Business School and professor at several other academic institutions in Europe and the United States. Prior to joining the EMA, he held leadership positions in the biopharmaceutical industry for more than eighteen years, covering international clinical development, pharmacovigilance, biostatistics and medical issues.

José Luis Fábregas
CMC

  • Read more

    Ph.D. in Analytical Chemistry (Autonomous University of Barcelona).

    Dr. Fábregas has extensive experience in management within the pharmaceutical industry, leading different disciplines related to chemistry, manufacturing and controls (CMC) which has supported the global development of pharmaceutical substances and products in the respiratory areas, central nervous system, gastrointestinal system and pain and inflammation.
    From 1993 to 2010, permanent member of the R & D Management Committee and the R & D Leadership Committee in Almirall.

 

 

Medical and Scientific Advisory Board

Prof. Uri Galili
KOL in anti-aGal antibodies

  • Read more

    Professor at Rush Medical College, (Chicago, USA) where he studies the regeneration of ischemic myocardium, after myocardial infarction, induced by nanoparticles with αGal.

    He discovered anti-αGal antibodies as the most abundant natural antibodies in humans. He also identified the α-gal epitope as the mammalian antigen that binds to anti-αGal antibodies, determined the unique evolution of anti-αGal antibodies and α-gal epitopes in primates and studied the molecular basis of this evolution.

    He has developed methods to use anti-αGal antibodies in several therapies, including: immunotherapy against cancer, to increase immunogenicity of vaccines, acceleration of wound healing and burns and induction of tissue regeneration.

Dr. Bonaventura Clotet
KOL in infectious diseases

  • Read more

    Head of the HIV Unit and director of the retrovirology laboratory "irsiCaixa" Foundation in the University Hospital "Germans Trias i Pujol", Spain.

    He is part of the Drug Resistance Mutation Group of the International AIDS Society and is also a member of the Board of Directors of IAS Global.

    He has published more than 500 articles in international journals, is co-director of AIDS CYBERJOURNAL and has been a member of the editorial board of AIDS Journal for 8 years. He is currently a reviewer for Lancet, JID, AIDS, CID, Antiviral Therapy, HIV Medicine, JAC and JAIDS.

Prof. Nicolai Bovin
KOL in Carbohydrate Chemestry ans Glycomics 

  • Read more

    His research focuses on the basic problems of glycobiology and the application of glyco-molecules in medicine. The main investigations include the synthesis of oligosaccharides and glycoconjugates, self-assembled peptides, carbohydrate-protein interactions, innate immunity to carbohydrates and the study of cell surface lectins and influenza virus.

    He has founded two companies (Lectinity and Semiotik, Russia) and is the author of 359 scientific articles.

Prof. Rafael Cantón, España
KOL in antimicrobial resistances

  • Read more

    Head of the Department of Clinical Microbiology at the Ramón y Cajal University Hospital (Madrid, Spain), researcher at the Ramón y Cajal Institute for Health Research (IRYCIS) and associate professor of Clinical Microbiology.

    Vice-president of the Spanish Society of Infectious Diseases and Clinical Microbiology, ad hoc member of the Steering Committee of the European Society of Clinical Microbiology and Infectious Diseases and president of the European Committee of Antimicrobial Susceptibility Tests. He is also associate editor of the journal Clinical Microbiology and Infection.

    He has published more than 300 articles in medical journals and 45 book chapters.